Table 4 Adverse events - incidence and grading according to CTCAE v 4.03
Toxicity | Overall incidence, no. (%) | Grade 1 and 2, no. (%) | Grade 3 and 4, no. (%) |
|---|---|---|---|
Hyperglycemia | 19 (79) | 19 (79) | |
Fatigue | 19 (79) | 18 (75) | 1 (4) |
Thrombocytopenia | 12 (50) | 12 (50) | |
Headache | 11 (46) | 10 (43) | 1 (4) |
Nausea | 10 (42) | 9 (38) | 1 (4) |
Leukopenia | 9 (38) | 9 (38) | |
ALT elevations | 8 (33) | 8 (33) | |
AST elevations | 7 (29) | 7 (29) | |
Bilirubin elevations | 5 (21) | 5 (21) | |
Neutropenia | 5 (21) | 5 (21) | |
Anemia | 5 (21) | 4 (17) | 1 (4) |
Seizures | 5 (21) | 4 (17) | 1 (4) |
Vomiting | 5 (21) | 4 (17) | 1 (4) |
Thyroid toxicity | 4 (17) | 4 (17) | |
Diarrhea | 4 (17) | 4 (17) | |
Myalgias/Arthralgias | 3 (13) | 3 (13) | |
Rash | 2 (8) | 2 (8) | |
Pyrexia | 2 (8) | 2 (8) | |
Lipase | 1 (4) | 1 (4) | |
Amylase | 1 (4) | 1 (4) | |
Mucositis | 1 (4) | 1 (4) |